GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Profitability Rank

VGI Health Technology (XNEC:VTL) Profitability Rank : 0 (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Profitability Rank?

VGI Health Technology has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

VGI Health Technology's Operating Margin % for the quarter that ended in . 20 was %. As of today, VGI Health Technology's Piotroski F-Score is 9999.


Competitive Comparison of VGI Health Technology's Profitability Rank

For the Biotechnology subindustry, VGI Health Technology's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VGI Health Technology's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Profitability Rank distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Profitability Rank falls into.



VGI Health Technology Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

VGI Health Technology has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

VGI Health Technology's Operating Margin % for the quarter that ended in . 20 is calculated as:

Operating Margin %=Operating Income (Q: . 20 ) / Revenue (Q: . 20 )
= /
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

VGI Health Technology has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


VGI Health Technology Profitability Rank Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


VGI Health Technology (XNEC:VTL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines